The Allergic Rhino-Conjunctivitis drugs in development market research report provides comprehensive information on the therapeutics under development for Allergic Rhino-Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Allergic Rhino-Conjunctivitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Allergic Rhino-Conjunctivitis and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Allergic Rhino-Conjunctivitis by nine companies/universities/institutes. The top development phase for Allergic Rhino-Conjunctivitis is phase iii with ten drugs in that stage. The Allergic Rhino-Conjunctivitis pipeline has 13 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Allergic Rhino-Conjunctivitis pipeline products market are: Inmunotek, Roxall Medizin and Allergy Therapeutics.
The key targets in the Allergic Rhino-Conjunctivitis pipeline products market include Interleukin 2 Receptor, Histamine H1 Receptor, and Calcineurin.
The key mechanisms of action in the Allergic Rhino-Conjunctivitis pipeline product include Calcineurin Inhibitor with one drug in Phase II. The Allergic Rhino-Conjunctivitis pipeline products include four routes of administration with the top ROA being Subcutaneous and three key molecule types in the Allergic Rhino-Conjunctivitis pipeline products market including Allergenics (Allergen), and Small Molecule.
Allergic Rhino-Conjunctivitis overview
Allergic Rhino-Conjunctivitis is an allergen-induced inflammatory response mediated by IgE and most observed in children and most rare in children above 5 years and in adults. Allergens release by plants, herbs, pollens, animal dander, dust mites are common mediators. It is preferable to allergic rhinitis. The most common nasal symptoms are sneezing, irritability, itching, runny nose and non-nasal are redness, eye itching. Past or family history of allergens, physical symptoms like redness, nasal congestion, and laboratory findings skin prick test or IgE antibodies levels in blood are the diagnostics measures. Symptomatic care, treatment with antibiotics to prevent secondary infections, intranasal corticosteroids, antihistamines like cetirizine, levocetirizine for treating rhino conjunctivitis or runny nose. Antipyretic medications paracetamol, leukotriene receptor antagonist montelukast. The condition can be prevented by less exposure to known allergens, avoidance of cold foods.
For a complete picture of Allergic Rhino-Conjunctivitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
